AZD 2927

Drug Profile

AZD 2927

Alternative Names: AZD2927

Latest Information Update: 09 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antiarrhythmics
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-II for Atrial fibrillation in Norway (IV)
  • 30 Jun 2012 Discontinued - Phase-II for Atrial fibrillation in Sweden (IV)
  • 13 Jan 2012 AstraZeneca completes a phase II trial in Atrial fibrillation in Sweden & Norway (NCT01396226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top